Skip to content

Author

Salomon Manier

We have 2 of 11 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Inflammatory bone marrow microenvironment impairs the therapeutic effect of daratumumab-lenalidomide in multiple myeloma

Daratumumab-lenalidomide (DR) combination therapy improves multiple myeloma (MM) outcomes, yet some patients respond poorly. We examined 21 DR pre-treatment samples from the IFM2017-03 phase 3 trial using single-cell and bulk multiomics approaches to identify determinants of response. Analysis of the bone marrow enviro...

Wen-Wen Cheng, S. Gaggero, Lama Hasan Bou Issa et al. · 0 citations
Open access Sep 2026

T-cell dynamics, CD8/NK ratio and tumor survival hallmarks determine response to T-cell bispecific forimtamig in myeloma.

T-cell bispecific (TCB) therapies have demonstrated promising therapeutic efficacies for patients with relapsed/refractory multiple myeloma. However, responses are transient and essentially all patients eventually relapse. Cytokine release syndrome and other on-target off-tumor toxicities are common. Together, these ch...

I. Dekhtiarenko, Jan Attig, I. Lelios et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.